Calypso Biotech Licenses IBD Treatment to EA Pharma

Calypso Biotech SA announced that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.

CALY-001 is a promising novel treatment for indications such as inflammatory bowel disease (IBD), potentially capable of preventing disease complications.

“This agreement highlights the strong potential for CALY-001, which possesses a unique mode of action through binding and inhibiting active MMP-9“ says Alain Vicari, CEO of Calypso Biotech. “By teaming with EA Pharma, a leader in gastrointestinal diseases with full value chain, we will fulfill our vision to bring new therapeutics to patients suffering from severe gastrointestinal diseases. Beyond IBD, CALY-001 represents a promising and advantageous therapeutic option for several oncology, inflammation and fibrosis indications”.

Under the agreement, Calypso Biotech will grant EA Pharma an exclusive and world-wide license for the development, manufacturing and marketing of CALY-001. Both companies will collaborate to develop CALY-001 for IBD. Calypso Biotech will receive an upfront, milestone and royalty payments from EA Pharma. Staatz Business Development & Strategy acted as transaction advisor to Calypso Biotech.